Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 3
2016 3
2019 1
2020 1
2021 3
2022 1
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up.
Pokorná Z, Kollárová-Brázdová P, Lenčová-Popelová O, Jirkovský E, Kubeš J, Mazurová Y, Adamcová M, Holečková M, Palička V, Šimůnek T, Štěrba M. Pokorná Z, et al. Among authors: lencova popelova o. Clin Sci (Lond). 2022 Jan 14;136(1):139-161. doi: 10.1042/CS20210836. Clin Sci (Lond). 2022. PMID: 34878093
In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline.
Pokorna Z, Jirkovsky E, Hlavackova M, Jansova H, Jirkovska A, Lencova-Popelova O, Brazdova P, Kubes J, Sotakova-Kasparova D, Mazurova Y, Adamcova M, Vostatkova L, Holzerova K, Kolar F, Simunek T, Sterba M. Pokorna Z, et al. Among authors: lencova popelova o. Clin Sci (Lond). 2019 Aug 27;133(16):1827-1844. doi: 10.1042/CS20190139. Print 2019 Aug 30. Clin Sci (Lond). 2019. PMID: 31409729
Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.
Jirkovský E, Jirkovská A, Bavlovič-Piskáčková H, Skalická V, Pokorná Z, Karabanovich G, Kollárová-Brázdová P, Kubeš J, Lenčová-Popelová O, Mazurová Y, Adamcová M, Lyon AR, Roh J, Šimůnek T, Štěrbová-Kovaříková P, Štěrba M. Jirkovský E, et al. Among authors: lencova popelova o. Circ Heart Fail. 2021 Nov;14(11):e008209. doi: 10.1161/CIRCHEARTFAILURE.120.008209. Epub 2021 Sep 23. Circ Heart Fail. 2021. PMID: 34551586
Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity.
Bavlovič Piskáčková H, Jansová H, Kubeš J, Karabanovich G, Váňová N, Kollárová-Brázdová P, Melnikova I, Jirkovská A, Lenčová-Popelová O, Chládek J, Roh J, Šimůnek T, Štěrba M, Štěrbová-Kovaříková P. Bavlovič Piskáčková H, et al. Among authors: lencova popelova o. Sci Rep. 2021 Feb 24;11(1):4456. doi: 10.1038/s41598-021-83688-x. Sci Rep. 2021. PMID: 33627707 Free PMC article.
Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo.
Kollárová-Brázdová P, Lenčová-Popelová O, Karabanovich G, Kocúrová-Lengvarská J, Kubeš J, Váňová N, Mazurová Y, Adamcová M, Jirkovská A, Holečková M, Šimůnek T, Štěrbová-Kovaříková P, Roh J, Štěrba M. Kollárová-Brázdová P, et al. Among authors: lencova popelova o. Clin Sci (Lond). 2021 Aug 13;135(15):1897-1914. doi: 10.1042/CS20210311. Clin Sci (Lond). 2021. PMID: 34318878
Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage.
Keresteš V, Kubeš J, Applová L, Kollárová P, Lenčová-Popelová O, Melnikova I, Karabanovich G, Khazeem MM, Bavlovič-Piskáčková H, Štěrbová-Kovaříková P, Austin CA, Roh J, Štěrba M, Šimůnek T, Jirkovská A. Keresteš V, et al. Among authors: lencova popelova o. Toxicol Sci. 2024 Mar 26;198(2):288-302. doi: 10.1093/toxsci/kfae008. Toxicol Sci. 2024. PMID: 38290791 Free PMC article.
Cardiac miRNA expression during the development of chronic anthracycline-induced cardiomyopathy using an experimental rabbit model.
Adamcova M, Parova H, Lencova-Popelova O, Kollarova-Brazdova P, Baranova I, Slavickova M, Stverakova T, Mikyskova PS, Mazurova Y, Sterba M. Adamcova M, et al. Among authors: lencova popelova o. Front Pharmacol. 2024 Jan 3;14:1298172. doi: 10.3389/fphar.2023.1298172. eCollection 2023. Front Pharmacol. 2024. PMID: 38235109 Free PMC article.
Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.
Lenčová-Popelová O, Jirkovský E, Jansová H, Jirkovská-Vávrová A, Vostatková-Tichotová L, Mazurová Y, Adamcová M, Chládek J, Hroch M, Pokorná Z, Geršl V, Šimůnek T, Štěrba M. Lenčová-Popelová O, et al. J Mol Cell Cardiol. 2016 Feb;91:92-103. doi: 10.1016/j.yjmcc.2015.12.021. Epub 2015 Dec 23. J Mol Cell Cardiol. 2016. PMID: 26724189
Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase IIβ Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity.
Kollárová-Brázdová P, Jirkovská A, Karabanovich G, Pokorná Z, Bavlovič Piskáčková H, Jirkovský E, Kubeš J, Lenčová-Popelová O, Mazurová Y, Adamcová M, Skalická V, Štěrbová-Kovaříková P, Roh J, Šimůnek T, Štěrba M. Kollárová-Brázdová P, et al. Among authors: lencova popelova o. J Pharmacol Exp Ther. 2020 Jun;373(3):402-415. doi: 10.1124/jpet.119.264580. Epub 2020 Apr 6. J Pharmacol Exp Ther. 2020. PMID: 32253261
Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?
Lenčová-Popelová O, Jansová H, Jirkovský E, Bureš J, Jirkovská-Vávrová A, Mazurová Y, Reimerová P, Vostatková L, Adamcová M, Hroch M, Pokorná Z, Kovaříková P, Šimůnek T, Štěrba M. Lenčová-Popelová O, et al. Toxicology. 2016 Nov 30;372:52-63. doi: 10.1016/j.tox.2016.11.002. Epub 2016 Nov 2. Toxicology. 2016. PMID: 27816693
15 results